Press releases
Company announcements
QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim to address high unmet needs in cancer patients
The collaboration was extended for two additional years following the successful completion of a major high-throughput screening campaign and the identification of attractive hits for further development.
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening
The first-ever simultaneous 10-target multiplexing high-throughput screen met all quality control criteria, achieved a 100% hit rate for both positive and negative controls, and identified high-quality hits across most of the selected targets.
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery
A strategic research collaboration with the group of Dr. Johannes Zuber at the Research Institute of Molecular Pathology to investigate the molecular functions of transcription factor complexes.
QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform
The Austrian Research Promotion Agency FFG awarded an 18-month grant in support of a EUR 1.7 million R&D project, catalysing the scale-up and multi-target profiling capability of QUANTRO’s platform to industrial level.
QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments
All pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished.
QUANTRO Therapeutics appoints industry expert Dr. Michael Bauer as Chief Executive Officer
Dr. Michael Bauer succeeded Dr. Dieter Nachtigall as CEO effective 1 May 2023, bringing a track record of advancing first-in-class cancer therapeutics into clinical development.
QUANTRO Therapeutics collaborates with Boehringer Ingelheim to develop drug candidates interfering with transcriptional regulators
A three-year collaboration, option and license agreement with Boehringer Ingelheim for the identification and development of inhibitors for up to three cancer-associated transcription factors.
QUANTRO Therapeutics appoints Dr. Elmar Maier as Chairman of the Advisory Board
Dr. Elmar Maier, who has been involved in founding several biotechnology companies over the past 25 years, was appointed Chairman of QUANTRO’s Advisory Board.
QUANTRO Therapeutics launched with breakthrough oncology drug discovery platform
QUANTRO established operations with seed financing from Boehringer Ingelheim Venture Fund and Evotec, introducing Transcriptional Fingerprinting to high-throughput, cell-based compound screening.